Fuad El-Hibri Wire

Emergent BioSolutions Inc. today announced the appointment of Allen Shofe to the position of Vice President of Government Affairs. Fuad El-Hibri appoints Allen Shofe Vice President of Government Affairs

Emergent BioSolutions Appoints Allen Shofe Vice President of Government Affairs

GAITHERSBURG, Md., Sept. 15 /PRNewswire/ — Emergent BioSolutions Inc. today announced the appointment of Allen Shofe to the position of Vice President of Government Affairs.  In this position, Mr. Shofe will be responsible for designing, implementing and overseeing all aspects of the company’s domestic and international government affairs initiatives.

“Allen is a versatile and highly astute government relations and public affairs executive,” said Fuad El-Hibri, CEO of Emergent BioSolutions.  “His government affairs expertise and extensive network of professional contacts throughout the United States and Europe will prove invaluable as we continue our efforts to become a global leader in our field.”

Mr. Shofe has more than 15 years experience in government relations and government affairs at the Federal and state levels, as well as in the international arena.  Mr. Shofe previously held the position of Director of Federal Government Relations at Eli Lilly and Company, where he managed a series of government initiatives, including those that focused on intellectual property, patent law and tort reform.  Mr. Shofe received his BA in International Relations/Diplomacy at the University of Minnesota and an LL.M, Master of Laws from the University of Leicester in the United Kingdom. “I look forward to the opportunity to help advance Emergent BioSolutions into a world class biopharmaceutical company,” said Mr. Shofe.  “This company has such a promising future, and to be a part of its growth and success is something I am extremely proud of.”

About Emergent BioSolutions
Emergent BioSolutions Inc., formed in 2004, is dedicated to the research, development and manufacture of novel products which harness the immune system to treat and prevent disease.  These include vaccines and related products for prophylactic and therapeutic use against common infectious diseases and biological weapons of mass destruction.  The company currently employs more than 450 people with facilities in Gaithersburg and Frederick, Maryland, Lansing, Michigan, Berkshire, U.K. and Munich Germany.  More information about Emergent BioSolutions and its subsidiaries can be found at http://www.ebsi.com

Emergent BioSolutions Inc. announced that the Drugs Controller General of India (DCGI) has issued a registration certificate for BioThrax (Anthrax Vaccine Adsorbed), which enables the marketing and sale of the vaccine in India to help prevent anthrax infection.

Fuad El-Hibri’s Emergent BioSolutions gets market authorization in India for BioThrax

According to a release, Emergent BioSolutions has signed a marketing agreement with Biological E. Limited for the marketing of BioThrax in India. BioThrax is the only vaccine for the prevention of anthrax infection licensed by the U.S. Food and Drug Administration (FDA).

The company noted that the BioThrax market authorization for India follows the publication in 2008 of the National Disaster Management Guidelines by the Indian National Disaster Management Authority (NDMA), which is the government body that oversees disaster management. In that document, the  government of India provided guidance with respect to the management of biological disasters and said that there is a need to have a supply of readily available anthrax vaccines to be administered rapidly in the event of an outbreak. The report goes on to state that all first responders will be vaccinated in an impending disaster situation.

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, said, “The Government of India has been explicit in expressing its commitment to protect its population from the continuing threat of bioterrorism. We are certainly pleased that BioThrax will be a valuable countermeasure available to the Government of India to achieve that goal. Today marks a pivotal milestone in Emergent’s efforts to expand globally and further our mission of protecting life.”

About BioThrax (Anthrax Vaccine Adsorbed): BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is licensed by the FDA as a pre-exposure prophylaxis for use in adults who are at high risk of exposure to anthrax spores. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis and contains no dead or live bacteria. Since 1998, the U.S. government has procured nearly 33.5 million doses of BioThrax. During that time period, nearly 8.4  million doses have been administered to more than 2.1 million military personnel. BioThrax cannot cause anthrax infection. Please visit emergentbiosolutions.com/pdf/emergent_biothrax_us.pdf for full prescribing information.

Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of immune-related biologic products, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Emergent BioSolutions Inc (EBS) click here. Emergent BioSolutions Inc (EBS) has Short Term PowerRatings of 1. Details on Emergent BioSolutions Inc (EBS) Short Term PowerRatings is available at This Link.

Posted in BioThrax, El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: Bacillus anthracis, BioThrax, Emergent BioSolutions, Government of India, India, United States, US Food and Drug Administration, Vaccine

Fuad El-Hibri EBS Typhoid Vaccine

Fuad El-Hibri and Emergent BioSolutions are handing our bonuses

Fuad El-Hibri and Emergent BioSolutions are handing our bonuses

Bonus may be a bad word right now — but not for a biotech that is actually making money.

Alongside minimal pay raises, Emergent BioSolutions Inc. execs received bonuses in 2008 that increased anywhere from 5 percent to 43 percent from their 2007 bonuses. Fuad El-Hibri, chief executive officer and chairman of the Rockville company, got the lowest increase, but the highest bonus at $323,250. The highest increase was doled out to Kyle Keese, senior vice president of manufacturing operations, who took home a $96,460 bonus for 2008.

Though, at least one manager’s perk wasn’t quite so perky last year. Robert Kramer, who stepped down in January as head of Emergent’s manufacturing subsidiary and instead will manage a contract that the company hopes to nail with the federal government this year, got a 48 percent decrease in his bonus from 2007, bringing his 2008 figure to $78,815.

While Emergent is one of the few biotechs netting a profit, its numbers did dip slightly from 2007 to 2008 — by 2 percent of revenue and 10 percent of profits — because of fewer or delayed shipments of its anthrax vaccine to the federal government. But whereas other biotechs have been shaving down their work forces, Emergent added people in 2008, up to 587 people from 560 in 2007.

---

Posted in El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: Chief executive officer, Emergent BioSolutions, Executive, Manufacturing, Manufacturing operations, Rockville, United States, Vice president

Posted in El-Hibri Fuad, Fuad El-Hibri, Yale School of Management
Tags: Class reunion, Education, High school, Michael Dowling, Military, REUNION, United States, Veterans

Fuad El-Hibri at Yale School of Management